289 related articles for article (PubMed ID: 20728206)
1. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
Katial RK; Strand M; Prasertsuntarasai T; Leung R; Zheng W; Alam R
J Allergy Clin Immunol; 2010 Oct; 126(4):738-44. PubMed ID: 20728206
[TBL] [Abstract][Full Text] [Related]
2. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
White AA; Stevenson DD; Simon RA
Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
[TBL] [Abstract][Full Text] [Related]
3. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease.
Lee JY; Simon RA; Stevenson DD
J Allergy Clin Immunol; 2007 Jan; 119(1):157-64. PubMed ID: 17208597
[TBL] [Abstract][Full Text] [Related]
4. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.
Berges-Gimeno MP; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2003 Mar; 90(3):338-41. PubMed ID: 12669898
[TBL] [Abstract][Full Text] [Related]
5. Sputum biomarkers during aspirin desensitization in nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.
Tyrak KE; Kupryś-Lipińska I; Czarnobilska E; Jakieła B; Pajdzik K; Ćmiel A; Plutecka H; Koziej M; Gawrońska A; Konduracka E; Kuna P; Sanak M; Mastalerz L
Respir Med; 2019 Jun; 152():51-59. PubMed ID: 31128610
[TBL] [Abstract][Full Text] [Related]
6. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
7. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation].
Xin XF; Zhao M; Li ZL; Song Y; Shi Y
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998
[TBL] [Abstract][Full Text] [Related]
8. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
Berges-Gimeno MP; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
[TBL] [Abstract][Full Text] [Related]
9. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
[TBL] [Abstract][Full Text] [Related]
10. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
Macy E; Bernstein JA; Castells MC; Gawchik SM; Lee TH; Settipane RA; Simon RA; Wald J; Woessner KM;
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):172-4. PubMed ID: 17304886
[TBL] [Abstract][Full Text] [Related]
11. [Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
Cardona R; Ramírez RH; Reina Z; Escobar MF; Morales E
Biomedica; 2009 Jun; 29(2):181-90. PubMed ID: 20128343
[TBL] [Abstract][Full Text] [Related]
12. [Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100 mg of aspirin a day].
Gosepath J; Schäfer D; Mann WJ
Laryngorhinootologie; 2002 Oct; 81(10):732-8. PubMed ID: 12397524
[TBL] [Abstract][Full Text] [Related]
13. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
White AA; Stevenson DD
Semin Respir Crit Care Med; 2012 Dec; 33(6):588-94. PubMed ID: 23047310
[TBL] [Abstract][Full Text] [Related]
14. Aspirin desensitization in aspirin-exacerbated respiratory disease.
White AA; Stevenson DD
Immunol Allergy Clin North Am; 2013 May; 33(2):211-22. PubMed ID: 23639709
[TBL] [Abstract][Full Text] [Related]
15. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Esmaeilzadeh H; Nabavi M; Aryan Z; Arshi S; Bemanian MH; Fallahpour M; Mortazavi N
Clin Immunol; 2015 Oct; 160(2):349-57. PubMed ID: 26083948
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
[TBL] [Abstract][Full Text] [Related]
17. Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma.
Amayasu H; Nakabayashi M; Akahori K; Ishizaki Y; Shoji T; Nakagawa H; Hasegawa H; Yoshida S
Ann Allergy Asthma Immunol; 2001 Aug; 87(2):146-50. PubMed ID: 11527248
[TBL] [Abstract][Full Text] [Related]
18. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation.
Rossini R; Angiolillo DJ; Musumeci G; Scuri P; Invernizzi P; Bass TA; Mihalcsik L; Gavazzi A
Am J Cardiol; 2008 Mar; 101(6):786-9. PubMed ID: 18328841
[TBL] [Abstract][Full Text] [Related]
19. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease.
Hope AP; Woessner KA; Simon RA; Stevenson DD
J Allergy Clin Immunol; 2009 Feb; 123(2):406-10. PubMed ID: 19056109
[TBL] [Abstract][Full Text] [Related]
20. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.
Lee RU; White AA; Ding D; Dursun AB; Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2010 Aug; 105(2):130-5. PubMed ID: 20674823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
